Hormonal
In overweight or obese patients with type 2 diabetes and severe insulin resistance, overriding insulin resistance with high-dose exogenous insulin therapy can induce insulin-mediated metabolic stress, leading to myocardial glucolipotoxicity and increased cardiovascular mortality.
If you have type 2 diabetes, are overweight, and struggle with high blood sugar despite lifestyle changes, aggressive insulin therapy might be doing more harm than good by stressing your heart. Instead of forcing glucose levels down with high insulin doses, focus on treatments that reduce the nutrient load (like weight loss or nutrient-offloading drugs) to respect your body's natural insulin resistance.
We propose that IR protects critical tissues, such as the heart, from nutrient-induced damage in this subgroup and that 'approaches' to intensively lower blood glucose that override IR (e.g., high-dose insulin therapy) will cause them harm.
Why this rating
Based on a synthesis of multiple major clinical trials (ACCORD, VADT, DIGAMI 2) showing increased mortality with intensive insulin therapy in obese/refractory patients, supported by mechanistic rodent and human studies.
Source
Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes
Christopher J. Nolan et al. · Diabetes · 2015
DOI 10.2337/db14-0694
More from this paper
- Insulin resistance in the myocardium serves as a protective mechanism against glucolipotoxicity by limiting glucose entry; overriding this resistance with high-dose insulin leads to mitochondrial dysfunction, oxidative stress, and cardiac injury.Good
- Intensive lifestyle interventions that reduce nutrient load (weight loss) improve cardiovascular outcomes in obese type 2 diabetes patients, whereas intensive insulin therapy in similar patients increases mortality.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →